Previous close | 0.1950 |
Open | 0.1950 |
Bid | 0.1950 x N/A |
Ask | 0.2000 x N/A |
Day's range | 0.1950 - 0.1950 |
52-week range | 0.1800 - 0.4950 |
Volume | |
Avg. volume | 439,368 |
Market cap | 49.776M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 0.87 |
Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its quarterly Emerging Growth Invitational investor conference on February 24, 2022. The conference, which is open to all retail and institutional investors, will consist of a series of twenty five
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Radiopharm Theranostics Ltd. (ASX: RAD). The in-depth 22-page initiation report includes detailed information on Radiopharm Theranostics Ltd.’s business model, services, industry, valuation, management, and risks. The full research report is available here. Highlights from the report include: Large Market Opportunity D